vs
Side-by-side financial comparison of Axil Brands, Inc. (AXIL) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Axil Brands, Inc. is the larger business by last-quarter revenue ($8.1M vs $5.5M, roughly 1.5× Taysha Gene Therapies, Inc.). Axil Brands, Inc. runs the higher net margin — 8.7% vs -507.8%, a 516.4% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs 5.2%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs 12.1%).
Axil Brands, Inc. is a U.S.-headquartered company that designs, manufactures and markets premium hearing protection products, audio enhancement devices and personal audio accessories. Its offerings include custom-fit earplugs, Bluetooth-enabled hearing buds for work, sports and leisure use, serving both consumer and professional segments across global markets.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
AXIL vs TSHA — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.1M | $5.5M |
| Net Profit | $704.9K | $-27.9M |
| Gross Margin | 68.1% | — |
| Operating Margin | 11.1% | -516.0% |
| Net Margin | 8.7% | -507.8% |
| Revenue YoY | 5.2% | 171.3% |
| Net Profit YoY | 11.2% | -48.3% |
| EPS (diluted) | $0.09 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.1M | $5.5M | ||
| Q3 25 | $6.9M | $0 | ||
| Q2 25 | $5.8M | $2.0M | ||
| Q1 25 | $6.9M | $2.3M | ||
| Q4 24 | $7.7M | $2.0M | ||
| Q3 24 | $5.9M | $1.8M | ||
| Q2 24 | $6.5M | $1.1M | ||
| Q1 24 | $6.5M | $3.4M |
| Q4 25 | $704.9K | $-27.9M | ||
| Q3 25 | $334.3K | $-32.7M | ||
| Q2 25 | $-245.6K | $-26.9M | ||
| Q1 25 | $576.7K | $-21.5M | ||
| Q4 24 | $633.7K | $-18.8M | ||
| Q3 24 | $-109.8K | $-25.5M | ||
| Q2 24 | $49.5K | $-20.9M | ||
| Q1 24 | $781.1K | $-24.1M |
| Q4 25 | 68.1% | — | ||
| Q3 25 | 67.6% | — | ||
| Q2 25 | 70.0% | — | ||
| Q1 25 | 71.7% | — | ||
| Q4 24 | 71.1% | — | ||
| Q3 24 | 71.0% | — | ||
| Q2 24 | 71.5% | — | ||
| Q1 24 | 71.5% | — |
| Q4 25 | 11.1% | -516.0% | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | 0.8% | -1347.1% | ||
| Q1 25 | 8.4% | -930.5% | ||
| Q4 24 | 8.7% | -985.8% | ||
| Q3 24 | -2.4% | -1448.4% | ||
| Q2 24 | 2.6% | -1915.4% | ||
| Q1 24 | -1.6% | -713.3% |
| Q4 25 | 8.7% | -507.8% | ||
| Q3 25 | 4.9% | — | ||
| Q2 25 | -4.3% | -1353.6% | ||
| Q1 25 | 8.3% | -935.2% | ||
| Q4 24 | 8.2% | -929.0% | ||
| Q3 24 | -1.9% | -1427.5% | ||
| Q2 24 | 0.8% | -1882.0% | ||
| Q1 24 | 12.1% | -705.4% |
| Q4 25 | $0.09 | $-0.08 | ||
| Q3 25 | $0.04 | $-0.09 | ||
| Q2 25 | $-0.03 | $-0.09 | ||
| Q1 25 | $0.07 | $-0.08 | ||
| Q4 24 | $0.08 | $-0.07 | ||
| Q3 24 | $-0.02 | $-0.10 | ||
| Q2 24 | $0.11 | $-0.09 | ||
| Q1 24 | $0.04 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.0M | $319.8M |
| Total DebtLower is stronger | $138.3K | — |
| Stockholders' EquityBook value | $11.1M | $246.9M |
| Total Assets | $16.2M | $343.3M |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.0M | $319.8M | ||
| Q3 25 | $4.1M | $297.3M | ||
| Q2 25 | $4.8M | $312.8M | ||
| Q1 25 | $4.7M | $116.6M | ||
| Q4 24 | $5.2M | $139.0M | ||
| Q3 24 | $4.1M | $157.7M | ||
| Q2 24 | $3.3M | $172.7M | ||
| Q1 24 | $4.9M | $124.0M |
| Q4 25 | $138.3K | — | ||
| Q3 25 | $139.2K | — | ||
| Q2 25 | $140.2K | — | ||
| Q1 25 | $141.0K | — | ||
| Q4 24 | $143.3K | — | ||
| Q3 24 | $144.3K | — | ||
| Q2 24 | $146.6K | — | ||
| Q1 24 | — | — |
| Q4 25 | $11.1M | $246.9M | ||
| Q3 25 | $10.2M | $219.0M | ||
| Q2 25 | $9.7M | $248.7M | ||
| Q1 25 | $9.7M | $55.1M | ||
| Q4 24 | $8.8M | $71.5M | ||
| Q3 24 | $7.9M | $88.8M | ||
| Q2 24 | $7.7M | $108.9M | ||
| Q1 24 | $8.8M | $53.8M |
| Q4 25 | $16.2M | $343.3M | ||
| Q3 25 | $15.4M | $316.6M | ||
| Q2 25 | $12.9M | $333.3M | ||
| Q1 25 | $13.0M | $138.4M | ||
| Q4 24 | $13.7M | $160.4M | ||
| Q3 24 | $11.4M | $180.2M | ||
| Q2 24 | $11.0M | $200.4M | ||
| Q1 24 | $12.7M | $153.0M |
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $934.8K | $-26.7M |
| Free Cash FlowOCF − Capex | $906.4K | — |
| FCF MarginFCF / Revenue | 11.1% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | 1.33× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $934.8K | $-26.7M | ||
| Q3 25 | $-739.2K | $-24.2M | ||
| Q2 25 | $194.4K | $-20.2M | ||
| Q1 25 | $-169.9K | $-22.0M | ||
| Q4 24 | $1.0M | $-18.3M | ||
| Q3 24 | $897.3K | $-21.6M | ||
| Q2 24 | $-336.6K | $-21.5M | ||
| Q1 24 | $-912.8K | $-19.8M |
| Q4 25 | $906.4K | — | ||
| Q3 25 | $-747.6K | $-24.3M | ||
| Q2 25 | — | — | ||
| Q1 25 | $-258.2K | — | ||
| Q4 24 | $941.1K | $-18.3M | ||
| Q3 24 | — | $-21.6M | ||
| Q2 24 | $-394.9K | $-21.7M | ||
| Q1 24 | $-922.1K | $-19.9M |
| Q4 25 | 11.1% | — | ||
| Q3 25 | -10.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -3.7% | — | ||
| Q4 24 | 12.2% | -905.5% | ||
| Q3 24 | — | -1210.9% | ||
| Q2 24 | -6.1% | -1951.9% | ||
| Q1 24 | -14.3% | -584.5% |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 0.9% | 0.1% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | 0.9% | 18.1% | ||
| Q1 24 | 0.1% | 4.1% |
| Q4 25 | 1.33× | — | ||
| Q3 25 | -2.21× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.29× | — | ||
| Q4 24 | 1.59× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -6.80× | — | ||
| Q1 24 | -1.17× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXIL
| Hearing Enhancement And Protection | $7.8M | 95% |
| Other | $378.9K | 5% |
TSHA
Segment breakdown not available.
